SE0202598D0 - Alpha-7 Nicotinic receptor agonists and statins in combination - Google Patents

Alpha-7 Nicotinic receptor agonists and statins in combination

Info

Publication number
SE0202598D0
SE0202598D0 SE0202598A SE0202598A SE0202598D0 SE 0202598 D0 SE0202598 D0 SE 0202598D0 SE 0202598 A SE0202598 A SE 0202598A SE 0202598 A SE0202598 A SE 0202598A SE 0202598 D0 SE0202598 D0 SE 0202598D0
Authority
SE
Sweden
Prior art keywords
statins
alpha
combination
receptor agonists
nicotinic receptor
Prior art date
Application number
SE0202598A
Other languages
English (en)
Swedish (sv)
Inventor
Richard Keith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202598A priority Critical patent/SE0202598D0/xx
Publication of SE0202598D0 publication Critical patent/SE0202598D0/xx
Priority to ES03791540T priority patent/ES2283860T3/es
Priority to HK05109104.9A priority patent/HK1077193B/en
Priority to EP03791540A priority patent/EP1545537B9/en
Priority to JP2004532517A priority patent/JP2006505530A/ja
Priority to US10/525,783 priority patent/US20050256146A1/en
Priority to SI200330803T priority patent/SI1545537T1/sl
Priority to PCT/SE2003/001352 priority patent/WO2004019947A1/en
Priority to AU2003256203A priority patent/AU2003256203A1/en
Priority to DE60313004T priority patent/DE60313004T2/de
Priority to DK03791540T priority patent/DK1545537T3/da
Priority to PT03791540T priority patent/PT1545537E/pt
Priority to AT03791540T priority patent/ATE358485T1/de
Priority to US12/186,915 priority patent/US20090192180A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE0202598A 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination SE0202598D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE0202598A SE0202598D0 (sv) 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination
AT03791540T ATE358485T1 (de) 2002-09-02 2003-09-01 Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
SI200330803T SI1545537T1 (sl) 2002-09-02 2003-09-01 Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji
HK05109104.9A HK1077193B (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and statins in combination
EP03791540A EP1545537B9 (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and statins in combination
JP2004532517A JP2006505530A (ja) 2002-09-02 2003-09-01 アルファ−７ニコチン受容体作用剤およびスタチンの組み合わせ
US10/525,783 US20050256146A1 (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and stains in combination
ES03791540T ES2283860T3 (es) 2002-09-02 2003-09-01 Agonistas deñ recptor nicotinico alfa-7 y estaninas combinados.
PCT/SE2003/001352 WO2004019947A1 (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and statins in combination
AU2003256203A AU2003256203A1 (en) 2002-09-02 2003-09-01 Alpha-7 nicotinic receptor agonists and statins in combination
DE60313004T DE60313004T2 (de) 2002-09-02 2003-09-01 Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
DK03791540T DK1545537T3 (da) 2002-09-02 2003-09-01 Alfa-7-nikotinreceptoragonister og statiner i kombination
PT03791540T PT1545537E (pt) 2002-09-02 2003-09-01 Agonistas do receptor alfa-7 nicotínico e estatinas em combinação
US12/186,915 US20090192180A1 (en) 2002-09-02 2008-08-06 Alpha-7 Nicotinic Receptor Agonists and Statins In Combination

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202598A SE0202598D0 (sv) 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination

Publications (1)

Publication Number Publication Date
SE0202598D0 true SE0202598D0 (sv) 2002-09-02

Family

ID=20288874

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202598A SE0202598D0 (sv) 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination

Country Status (12)

Country Link
US (2) US20050256146A1 (enExample)
EP (1) EP1545537B9 (enExample)
JP (1) JP2006505530A (enExample)
AT (1) ATE358485T1 (enExample)
AU (1) AU2003256203A1 (enExample)
DE (1) DE60313004T2 (enExample)
DK (1) DK1545537T3 (enExample)
ES (1) ES2283860T3 (enExample)
PT (1) PT1545537E (enExample)
SE (1) SE0202598D0 (enExample)
SI (1) SI1545537T1 (enExample)
WO (1) WO2004019947A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
ES2402084T3 (es) 2008-06-20 2013-04-26 Astrazeneca Ab Derivado de dibenzotiazepina y sus usos
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
TWI634119B (zh) * 2011-03-18 2018-09-01 美商健臻公司 葡萄糖神經醯胺合成酶抑制劑
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EA029430B1 (ru) 2013-06-21 2018-03-30 Такеда Фармасьютикл Компани Лимитед Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
US20210255202A1 (en) * 2018-06-13 2021-08-19 Michael R. D'Andrea Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA54375C2 (uk) * 1994-08-24 2003-03-17 Астра Актієболаг Спіро-азабіциклічні сполуки, способи їх одержання та фармацевтична композиція
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903996D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
US20050222122A1 (en) * 2002-04-02 2005-10-06 Sean Lilienfeld Statin therapy for enhancing cognitive maintenance
JP2006510662A (ja) * 2002-12-11 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療
BRPI0508771A (pt) * 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos

Also Published As

Publication number Publication date
DE60313004D1 (de) 2007-05-16
ATE358485T1 (de) 2007-04-15
EP1545537B9 (en) 2008-08-20
PT1545537E (pt) 2007-06-20
EP1545537B1 (en) 2007-04-04
US20090192180A1 (en) 2009-07-30
EP1545537A1 (en) 2005-06-29
US20050256146A1 (en) 2005-11-17
HK1077193A1 (en) 2006-02-10
WO2004019947A1 (en) 2004-03-11
AU2003256203A1 (en) 2004-03-19
JP2006505530A (ja) 2006-02-16
SI1545537T1 (sl) 2007-08-31
DK1545537T3 (da) 2007-07-02
ES2283860T3 (es) 2007-11-01
DE60313004T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
TW200510416A (en) P38 inhibitors and methods of use thereof
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
IL251185A0 (en) mek inhibitors and methods of using them
HUS1700003I1 (hu) Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
ATE448686T1 (de) Actriib-fusionspolypeptide und verwendungen dafür
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
MY142777A (en) Substituted indole-o-glucosides
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
UA87991C2 (en) Substituted indole-o-glucosides
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.